WAVEMAN · COMPANY

RNA · Atrium Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

RNA

Name: Atrium Therapeutics, Inc. (RNA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Atrium Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002093101

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-21.9%

XBRL, annual

NET MARGIN

-672.0%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

87 funds added or opened last quarter

more than 61% of Pharma & Biotech

REVENUE

-21.9% year over year (latest quarter)

below 75% of Pharma & Biotech

MARGIN

-672.0% net margin (latest quarter)

below 85% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

87 funds added or opened positions in the latest 13F quarter, of 158 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -4.7%

-4.7%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 87 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Atrium Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Hughes Steven George

Chief Medical Officer

SELL

2026-01-21

2,017.0

$146.1K

Hughes Steven George

Chief Medical Officer

SELL

2026-01-21

2,878.0

$208.5K

Boyce Sarah

President and CEO

SELL

2026-01-21

6,394.0

$463.2K

Boyce Sarah

President and CEO

SELL

2026-01-21

7,993.0

$579.1K

Flanagan W. Michael

Chief Scientific Officer

SELL

2026-01-21

2,558.0

$185.3K

152 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 147 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Sessa Capital IM, L.P.

1,500,000.0 sh

$20.2M

BlackRock, Inc.

1,447,476.0 sh

$19.5M

CRCM LP

1,283,078.0 sh

$17.3M

VANGUARD CAPITAL MANAGEMENT LLC

730,831.0 sh

$9.8M

TIG Advisors, LLC

561,533.0 sh

$7.6M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Janus Henderson Small Cap Growth Alpha ETF

$1.5M POSITION · AS OF 2026-04-30

0.5%

AlphaCentric Life Sciences and Healthcare Fund

$177.6K POSITION · AS OF 2026-03-31

0.5%

NexPoint Event Driven Fund

$134.1K POSITION · AS OF 2026-03-31

0.2%

Nexpoint Merger Arbitrage Fund

$1.8M POSITION · AS OF 2026-03-31

0.1%

Goldman Sachs Small Cap Growth Insights Fund

$270.9K POSITION · AS OF 2026-04-30

0.1%

Health Sciences Trust

$199.2K POSITION · AS OF 2026-03-31

0.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Multi-phase

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED